乳腺癌保乳手术的安全切缘

摘要/Abstract

摘要：保乳手术现已成为早期乳腺癌的首选治疗手段，但安全切缘仍然是困扰着外科医生实施保乳手术的重要问题之一。由于多种临床因素对安全切缘存在一定的影响，目前对保乳手术安全切缘并未达成相关共识，存在一定的争议。

许睿，钱军. 乳腺癌保乳手术的安全切缘[J]. 国际肿瘤学杂志, 2016, 43(6): 458-461.

Xu Rui, Qian Jun. Safe margin of breast conserving surgery for breast cancer[J]. Journal of International Oncology, 2016, 43(6): 458-461.

［1］ Fisher B, Anderson S, Bryant J, et al. Twentyyear followup of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer［J］. N Engl J Med, 2002, 347(16): 1233-1241. DOI: 10.1056/NEJMoa022152 ［2］ McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery［J］. JAMA, 2012, 307(5): 467-475. DOI: 10.1001/jama.2012.43. ［3］ Biglia N, Ponzone R, Bounous VE, et al. Role of reexcision for positive and close resection margins in patients treated with breastconserving surgery［J］. Breast, 2014, 23(6): 870-875. DOI: 10.1016/j.breast.2014.09.009. ［4］ Houssami N, Macaskill P, Marinovich ML, et al. Metaanalysis of the impact of surgical margins on local recurrence in women with earlystage invasive breast cancer treated with breast conserving surgery［J］. Eur J Cancer, 2010, 46(18): 3219-3232. DOI: 10.1016/j.ejca.2010.07.043. ［5］ Behm EC, Beckmann KR, Dahlstrom JE, et al. Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10year data from the Breast Cancer Treatment Quality Assurance Project［J］. Breast, 2013, 22(5): 839-844. DOI: 10.1016/j.breast.2013.02.018. ［6］ Dillon MF, Hill AD, Quinn CM, et al. A pathologic assessment of adequate margin status in breastconserving therapy［J］. Ann Surg Oncol, 2006, 13(3): 333-339. DOI: 10.1245/ASO.2006.03.098 ［7］ Azu M, Abrahamse P, Katz SJ, et al. What is an adequate margin for breastconserving surgery? Surgeon attitudes and correlates［J］. Ann Surg Oncol, 2010, 17(2): 558-563. DOI: 10.1245/s10434-009-0765-1. ［8］ Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical OncologyAmerican Society for Radiation Oncology consensus guideline on margins for breastconserving surgery with wholebreast irradiation in stages Ⅰ and Ⅱ invasive breast cancer［J］. Ann Surg Oncol, 2014, 21(3): 704-716. DOI: 10.1245/s10434-014-3481-4. ［9］ Bhatti AB, Khan A, Muzaffar N, et al. Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors［J］. World J Surg, 2014, 38(11): 2863-2870. DOI: 10.1007/s00268-014-2651-7. ［10］ Groot G, Rees H, Pahwa P, et al. Predicting local recurrence following breastconserving therapy for early stage breast cancer: the significance of a narrow (≤ 2 mm) surgical resection margin［J］. J Surg Oncol, 2011, 103(3): 212-216. DOI: 10.1002/jso.21826. ［11］ Gangi A, Chung A, Mirocha J, et al. Breastconserving therapy for triplenegative breast cancer［J］. JAMA Surg, 2014, 149(3): 252-258. DOI: 10.1001/jamasurg.2013.3037. ［12］ Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triplenegative breast cancer after breastconserving surgery and radiation［J］. Cancer, 2009, 115(5): 946-951. DOI: 10.1002/cncr.24094. ［13］ Bhatti AB, Khan AI, Siddiqui N, et al. Outcomes of triplenegative versus nontriplenegative breast cancers managed with breastconserving therapy［J］. Asian Pac J Cancer Prev, 2014, 15(6): 2577-2581. DOI: 10.7314/APJCP.2014.15.6.2577. ［14］ Pilewskie M, Ho A, Orell E, et al. Effect of margin width onlocal recurrence in triplenegative breast cancer patients treated with breastconserving surgery［J］. Ann Surg Oncol, 2013, 20(7): 2140-2147. DOI: 10.1245/s10434-013-3416-5. ［15］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［16］ Wapnir IL, Dignam JJ, Fisher B, et al. Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B17 and B24 randomized clinical trials for DCIS［J］. J Natl Cancer Inst, 2011, 103(6): 478-488. DOI: 10.1093/jnci/djr027. ［17］ Warnberg F, Garmo H, Emdin S, et al. Effect of radiotherapy after breastconserving surgery for ductal carcinoma in situ: 20 years followup in the randomized SweDCIS Trial［J］. J Clin Oncol, 2014, 32(32): 3613-3618. DOI: 10.1200/JCO.2014.56.2595. ［18］ Wai ES, Lesperance ML, Alexander CS, et al. Predictors of local recurrence in a populationbased cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone［J］. Ann Surg Oncol, 2011, 18(1):119-124. DOI: 10.1245/s10434-010-1214-x. ［19］ Zee KJ, Subhedar P, Olcese C, et al. Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2 996 women treated with breastconserving surgery for 30 years［J］. Ann Surg, 2015, 262(4): 623-631. DOI: 10.1097/SLA.0000000000001454. ［20］ Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ［J］. J Clin Oncol, 2009, 27(10): 1615-1620. DOI: 10.1200/JCO.2008.17.5182. ［21］ Ciocca RM, Li T, Freedman GM, et al. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breastconserving therapy［J］. Ann Surg Oncol, 2008, 15(8): 2263-2271. DOI: 10.1200/JCO.2008.17.5182. ［22］ Sadek BT, Shenouda MN, Abi Raad RF, et al. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is reexcision necessary?［J］. Int J Radiat Oncol, 2013, 87(4): 726-730. DOI: 10.1016/j.ijrobp.2013.08.012. ［23］ Galimberti V, Maisonneuve P, Rotmensz N, et al. Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology［J］. Ann Surg, 2011, 253(3): 580-584. DOI: 10.1097/SLA.0b013e31820d9a81. ［24］ Bartelink H, Maingon P, Poortmans P, et al. Wholebreast irradiation with or without a boost for patients treated with breastconserving surgery for earlybreast cancer: 20year followup of a randomised phase 3 trial［J］. Lancet Oncol, 2015, 16(1): 47-56. DOI: 10.1016/S14702045(14)71156-8. ［25］ Kunkler IH, Williams LJ, Jack WJ, et al. Breastconserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial［J］. Lancet Oncol, 2015, 16(3): 266-273. DOI: 10.1016/S1470-2045(14)71221-5. ［26］ Livi L, Meattini I, Franceschini D, et al. Radiotherapy boost doseescalation for invasive breast cancer after breastconserving surgery: 2 093 patients treated with a prospective margindirected policy［J］. Radiother Oncol, 2013, 108(2): 273-278. DOI: 10.1016/j.radonc.2013.02.009. [27] Anderson S, Wapnir I, Dignam J, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer[J]. J Clin Oncol, 2009, 27(15): 2466-2473. DOI: 10.1200/JCO.2008.19.8424. [28] Smith SL, Truong PT, Lu L, et al. Identification of patients at very low risk of local recurrence after breast-conserving surgery[J]. Int J Radiat Oncol Biol Phys, 2014, 89(3): 556-562. DOI: 10.1016/j.ijrobp.2014.03.016.

[1]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙.乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷.中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰.miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏.HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林.贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞.PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰.老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.

Safe margin of breast conserving surgery for breast cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价